Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antares Pharma, Inc.
Trial of needle-free drug delivery system begins
May 14th, 2003
Antares Pharma, Inc., (ANTR) announced that IKP (Institut fur Klinische Pharmakologie), a contract research organization (CRO) located in Grunstadt, Germany, has received approval and begun the clinical study defined in the extension of Antares Pharma's option agreement with Eli Lilly and Company (LLY). This agreement was extended in December 2002 in order to conduct an additional clinical study to support Lilly's evaluation of Antares Pharma's needle-free drug delivery technology. Roger G. Harrison, CEO and president of Antares Pharma, said, "We are pleased with the progress made since the announcement of the extension of our option agreement with...
Source: Biotech Week (2003-05-14)
|
